Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

1.

Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study.

Roy A, Cunningham D, Hawkins R, Sörbye H, Adenis A, Barcelo JR, Lopez-Vivanco G, Adler G, Canon JL, Lofts F, Castanon C, Fonseca E, Rixe O, Aparicio J, Cassinello J, Nicolson M, Mousseau M, Schalhorn A, D'Hondt L, Kerger J, Hossfeld DK, Garcia Giron C, Rodriguez R, Schoffski P, Misset JL.

Br J Cancer. 2012 Jul 24;107(3):435-41. doi: 10.1038/bjc.2012.286. Epub 2012 Jul 5.

PMID:
22767144
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma.

Roy AC, Park SR, Cunningham D, Kang YK, Chao Y, Chen LT, Rees C, Lim HY, Tabernero J, Ramos FJ, Kujundzic M, Cardic MB, Yeh CG, de Gramont A.

Ann Oncol. 2013 Jun;24(6):1567-73. doi: 10.1093/annonc/mdt002. Epub 2013 Feb 13.

PMID:
23406728
[PubMed - indexed for MEDLINE]
Free Article
3.

Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.

Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, Majlis A, Assadourian S, Van Cutsem E.

J Clin Oncol. 2005 Aug 20;23(24):5660-7.

PMID:
16110025
[PubMed - indexed for MEDLINE]
Free Article
4.

Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer.

Hawkes E, Okines AF, Papamichael D, Rao S, Ashley S, Charalambous H, Koukouma A, Chau I, Cunningham D.

Eur J Cancer. 2011 May;47(8):1146-51. doi: 10.1016/j.ejca.2010.12.021. Epub 2011 Jan 25.

PMID:
21269822
[PubMed - indexed for MEDLINE]
5.

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial.

Tebbutt NC, Cummins MM, Sourjina T, Strickland A, Van Hazel G, Ganju V, Gibbs D, Stockler M, Gebski V, Zalcberg J; Australasian Gastro-Intestinal Trials Group.

Br J Cancer. 2010 Feb 2;102(3):475-81. doi: 10.1038/sj.bjc.6605522. Epub 2010 Jan 12.

PMID:
20068567
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.

Thuss-Patience PC, Kretzschmar A, Repp M, Kingreen D, Hennesser D, Micheel S, Pink D, Scholz C, Dörken B, Reichardt P.

J Clin Oncol. 2005 Jan 20;23(3):494-501.

PMID:
15659494
[PubMed - indexed for MEDLINE]
Free Article
8.

Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.

Kim JA, Lee J, Han B, Park SH, Park JO, Park YS, Lim HY, Kang WK.

Cancer Chemother Pharmacol. 2011 Jul;68(1):177-84. doi: 10.1007/s00280-010-1452-4. Epub 2010 Sep 28.

PMID:
20878159
[PubMed - indexed for MEDLINE]
9.

Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.

Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Köberle D, Borner MM, Rufibach K, Maibach R, Wernli M, Leslie M, Glynne-Jones R, Widmer L, Seymour M, de Braud F; Swiss Group for Clinical Cancer Research.

J Clin Oncol. 2007 Aug 1;25(22):3217-23.

PMID:
17664469
[PubMed - indexed for MEDLINE]
Free Article
10.

Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial.

Dalla Chiesa M, Tomasello G, Buti S, Rovere RK, Brighenti M, Lazzarelli S, Donati G, Passalacqua R.

Cancer Chemother Pharmacol. 2011 Jan;67(1):41-8. doi: 10.1007/s00280-010-1281-5. Epub 2010 Mar 5.

PMID:
20204366
[PubMed - indexed for MEDLINE]
11.

Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study.

Constenla M, Garcia-Arroyo R, Lorenzo I, Carrete N, Campos B, Palacios P.

Gastric Cancer. 2002;5(3):142-7.

PMID:
12378340
[PubMed - indexed for MEDLINE]
12.

Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.

Loupakis F, Masi G, Fornaro L, Vasile E, Allegrini G, Fontana E, Granetto C, Salvatore L, Mentuccia L, Andreuccetti M, Cortesi E, Merlano M, Cascinu S, Falcone A.

Cancer Chemother Pharmacol. 2010 Aug;66(3):559-66. doi: 10.1007/s00280-009-1196-1. Epub 2010 Mar 17.

PMID:
20237927
[PubMed - indexed for MEDLINE]
13.

Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma.

Park SR, Chun JH, Yu MS, Lee JH, Ryu KW, Choi IJ, Kim CG, Lee JS, Kim YW, Bae JM, Kim HK.

Br J Cancer. 2006 May 22;94(10):1402-6.

PMID:
16641896
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803).

Yamamoto N, Fukuoka M, Negoro SI, Nakagawa K, Saito H, Matsui K, Kawahara M, Senba H, Takada Y, Kudoh S, Nakano T, Katakami N, Sugiura T, Hoso T, Ariyoshi Y.

Br J Cancer. 2004 Jan 12;90(1):87-92.

PMID:
14710212
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study.

Polyzos A, Felekouras E, Karatzas T, Griniatsos J, Dimitroulis D, Polyzos K, Kontzoglou K, Mantas D, Karavokyros J, Nikiteas N, Tsavaris N, Syrigos K, Vafiadis I.

Anticancer Res. 2012 Sep;32(9):4151-6.

PMID:
22993377
[PubMed - indexed for MEDLINE]
16.

Dose-dense chemotherapy in metastatic gastric cancer with a modified docetaxel-cisplatin-5-fluorouracil regimen.

Tomasello G, Chiesa MD, Buti S, Brighenti M, Negri F, Rovere RK, Martinotti M, Buononato M, Brunelli A, Lazzarelli S, Donati G, Passalacqua R.

Tumori. 2010 Jan-Feb;96(1):48-53.

PMID:
20437857
[PubMed - indexed for MEDLINE]
17.

A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer.

Sym SJ, Chang HM, Kang HJ, Lee SS, Ryu MH, Lee JL, Kim TW, Yook JH, Oh ST, Kim BS, Kang YK.

Cancer Chemother Pharmacol. 2008 Dec;63(1):1-8. doi: 10.1007/s00280-008-0701-2. Epub 2008 Feb 21.

PMID:
18288477
[PubMed - indexed for MEDLINE]
18.

Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial.

Gubanski M, Johnsson A, Fernebro E, Kadar L, Karlberg I, Flygare P, Berglund A, Glimelius B, Lind PA; Gastric Cancer Taxotere vs. Campto Trial (GATAC) Study Group.

Gastric Cancer. 2010 Aug;13(3):155-61. doi: 10.1007/s10120-010-0553-4. Epub 2010 Sep 5.

PMID:
20820984
[PubMed - indexed for MEDLINE]
19.

Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum.

Yi JH, Lee J, Lee J, Park SH, Park JO, Yim DS, Park YS, Lim HY, Kang WK.

Br J Cancer. 2012 Apr 24;106(9):1469-74. doi: 10.1038/bjc.2012.100. Epub 2012 Mar 29.

PMID:
22460270
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma.

Guo JF, Zhang B, Wu F, Wang B, Xing H, Zhu GY, Nie XY, Peng J.

Chin J Cancer. 2010 Mar;29(3):321-4.

PMID:
20193118
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk